Category News

Avenzo

Avenzo Therapeutics to Share Phase 1 AVZO-021 (CDK2 Inhibitor) Data at the 2026 American Society of Clinical Oncology Annual Meeting

Avenzo Therapeutics to Present New Phase 1 Data on AVZO-021 (CDK2 Inhibitor) at the 2026 American Society of Clinical Oncology Annual Meeting Avenzo Therapeutics has announced a significant milestone in…

Read MoreAvenzo Therapeutics to Share Phase 1 AVZO-021 (CDK2 Inhibitor) Data at the 2026 American Society of Clinical Oncology Annual Meeting